
AbCellera Biologics EPS Ratio | ABCL
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.49 | -0.55 | -0.51 | 0.56 | 0.56 | 0.53 | -0.01 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.56 | -0.55 | 0.0129 |
Quarterly EPS Ratio AbCellera Biologics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.13 | -0.18 | -0.14 | - | -0.19 | -0.12 | -0.15 | - | -0.17 | -0.13 | -0.14 | - | -0.1 | -0.11 | -0.14 | - | 0.09 | -0.02 | 0.59 | - | -0.08 | -0.01 | 0.43 | - | -0.02 | 0.03 | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.59 | -0.19 | -0.0333 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kodiak Sciences
KOD
|
-4.32 | $ 97.05 | -0.87 % | $ 5.16 B | ||
|
Karyopharm Therapeutics
KPTI
|
-17.9 | $ 0.02 | -56.5 % | $ 219 | ||
|
BioAtla
BCAB
|
0.27 | $ 1.74 | 0.64 % | $ 102 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
1.75 | - | - | $ 3.85 B | ||
|
UroGen Pharma Ltd.
URGN
|
-3.19 | $ 28.91 | -8.89 % | $ 1.39 B | ||
|
Catalyst Biosciences
CBIO
|
0.06 | $ 13.01 | 0.74 % | $ 1.16 B | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
ADiTx Therapeutics
ADTX
|
-1.15 K | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
-3.27 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
13.8 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
-1.96 | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
0.18 | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
-24.7 | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
-4.05 | - | 1083.1 % | $ 745 M | ||
|
AstraZeneca PLC
AZN
|
6.6 | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
-3.17 | $ 0.23 | -12.11 % | $ 16.8 K | ||
|
Bio-Path Holdings
BPTH
|
-4.12 | - | - | $ 100 K | ||
|
Cara Therapeutics
CARA
|
-2.46 | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
0.22 | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
-1.91 | - | -16.75 % | $ 25.8 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-0.08 | - | -5.98 % | $ 34.1 M | ||
|
Diffusion Pharmaceuticals
DFFN
|
-2.98 | - | 11.68 % | $ 8.97 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
-0.86 | - | -5.68 % | $ 8.28 M | ||
|
Enochian Biosciences
ENOB
|
-1.06 | - | - | $ 40.5 M | ||
|
Esperion Therapeutics
ESPR
|
-0.11 | - | - | $ 661 M | ||
|
Evofem Biosciences
EVFM
|
-0.11 | - | 7.55 % | $ 38.1 M | ||
|
Eyenovia
EYEN
|
-9.4 | - | 49.81 % | $ 13.2 M | ||
|
FibroGen
FGEN
|
45.4 | - | - | $ 889 M | ||
|
Homology Medicines
FIXX
|
2.42 | - | 0.77 % | $ 53.4 M | ||
|
Amicus Therapeutics
FOLD
|
-0.09 | - | - | $ 4.47 B | ||
|
Frequency Therapeutics
FREQ
|
-12.5 | - | - | $ 528 M | ||
|
Galecto
GLTO
|
3.98 | - | - | $ 762 M | ||
|
GlycoMimetics
GLYC
|
-0.59 | - | 9357.83 % | $ 1.01 B | ||
|
Graybug Vision
GRAY
|
-1.97 | - | -11.23 % | $ 9.65 M | ||
|
Galera Therapeutics
GRTX
|
0.64 | - | -32.59 % | $ 7.61 M | ||
|
Happiness Biotech Group Limited
HAPP
|
0.75 | - | 1.35 % | $ 17.8 M | ||
|
Novavax
NVAX
|
2.72 | $ 7.47 | -3.24 % | $ 1.21 B | ||
|
Hepion Pharmaceuticals
HEPA
|
-0.88 | - | -18.79 % | $ 39.3 K | ||
|
Hoth Therapeutics
HOTH
|
-0.9 | - | - | $ 18.8 M | ||
|
IMARA
IMRA
|
-1.83 | - | 15.96 % | $ 663 M | ||
|
KalVista Pharmaceuticals
KALV
|
-2.03 | - | - | $ 1.45 B | ||
|
KemPharm
KMPH
|
1.4 | - | -0.34 % | $ 200 M | ||
|
Kezar Life Sciences
KZR
|
-7.66 | - | - | $ 53.3 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
-1.59 | - | - | $ 63.4 M |